Cytoreductive surgery (CRS) is a surgical procedure that helps treat ovarian cancer. This procedure is beneficial for reducing the cancer cell in the abdominal cavity of patients with tumours. CRS is often combined with hyperthermic intraperitoneal chemotherapy (HIPEC). In the case of specific cancer treatments, this surgical procedure increases life expectancy by reducing the recurrence rate.
For patients with Stage III epithelial ovarian cancer, besides HIPEC, the cytoreductive interval surgery resulted in more prolonged recurrence-free survival and overall survival than surgery.
For colorectal cancer patients with peritoneal cytoreductive surgery, the addition of HIPEC can be used to prolong the overall survival of patients.
The Outcomes of Treatment
In a presentation at the annual meeting of the Southwestern Surgical Congress in April 2015, a team of experts presented the findings of the study of intermediate-term outcomes for patients with peritoneal carcinomatosis who are treated with Cytoreductive Surgery and HIPEC. The study was conducted with 48 persons. Among those, 24 were men, and 24 were women. They had to undergo cytoreductive surgery and HIPEC.
One of the most common primary tumours was mucinous adenocarcinoma of the appendix. The second most common tumour was colorectal adenocarcinoma. The majority of low-grade tumours are equal to high and intermediate grade. The majority of the operations were with curative intent.
The result of the study indicate:
The complete cytoreduction score was obtained in 64.1 percent of patients who were operated on with curative intent.
With a record of 12 months of follow-up, 47.9 percent of patients still need the evidence.
Median recurrence-free survival. The primary endpoint was 19.3 months and 19 percent at two years. The patients had no evidence of disease.
For patients undergoing curative intent, median recurrence-free survival was 23 months and 25 percent.
The study showed that HIPEC is one of the most successful treatment methods for some selected patients. HIPEC is the standard treatment for metastatic appendiceal cancer and peritoneal mesothelioma. The study team states that the initial outcomes will be improved based on resectable appendiceal cancer, metastatic colon cancer, and peritoneal mesothelioma. Visit our cancer care hospital in Mysore for the best treatment.
How is the Cytoreductive Surgery Conducted?
The primary type of cytoreductive surgery is performed to address ovarian cancer. It is known as exploratory laparotomy. It is also called upfront cytoreductive surgery. When conducting laparotomy, the surgeon removes as much cancer as possible by diagnosing and staging cancer accurately. The cancer is removed from the abdominal and pelvic regions. It is a complex surgery that includes:
Removal of cancerous tissue and other nearby organs.
The gynecologic oncologist will collect the tissue samples from the upper abdomen during surgery. The doctor will take the biopsy by collecting small amounts of abdominal fluid and removing nearby lymph nodes. Later these samples are examined by a microscope to confirm the cancer stage.
After undergoing complete cytoreductive surgery, the patients will be systematically given chemotherapy. During the procedure, the patient will be recommended for physical examination, imaging test, and CA-125 blood test. These procedures are helpful for the evaluation of cancer and the effectiveness of the treatment. After going through the complete procedure of ovarian cancer, the patients begin the surveillance program that continues for five years. Book an appointment to have the best treatment.